心泰医疗2023年度报告

Stock Code 股份代號 : 2291 ANNUAL REPORT2023年 度 報 告 Contents Definitions Inthis annual report,the following expressions have themeanings set out below unless the context requires otherwise: Definitions Lepu India Definitions “Shares” “Substantial Shareholder(s)” Definitions United States dollars, the lawful currency of the United States ofAmerica Corporate Information BOARD OF DIRECTORS Executive DirectorMs. Chen Juan(Chairwoman) Non-Executive Directors 20243 1 Ms. Zhang Yuxin(redesignated on March 1, 2024)Mr. Fu ShanMr. Zheng Guorui Independent Non-Executive Directors Ms. Chan Ka Lai VanessaMr. Zheng YufengMr. Liu Daozhi SUPERVISORS Mr. Wang XinglinMs. Wang XiaoyongMr. Qian Weidong AUDIT COMMITTEE Ms. Chan Ka Lai Vanessa(Chairperson)Mr. Zheng GuoruiMr. Zheng Yufeng REMUNERATION COMMITTEE Mr. Zheng Yufeng(Chairperson)Ms. Chen JuanMr. Fu ShanMs. Chan Ka Lai VanessaMr. Liu Daozhi NOMINATION COMMITTEE Ms. Chen Juan(Chairperson)Mr. Zheng GuoruiMs. Chan Ka Lai VanessaMr. Zheng YufengMr. Liu Daozhi Corporate Information JOINT COMPANY SECRETARIES 20237 1820237 18 Mr. Qin XueMs. Ko Mei Ying(appointed on July 18, 2023)Ms. Ng Ka Man(resigned on July 18, 2023) AUTHORIZED REPRESENTATIVES 20243 120243 1 Ms. Chen JuanMs. Ko Mei Ying(appointed on March 1, 2024)Ms. Zhang Yuxin(resigned on March 1, 2024) LEGAL ADDRESS IN THE PRC 25841201 Room 201Building 41No. 258, Xinzhuan RoadSongjiang DistrictShanghaiPRC ADDRESS OF HEAD OFFICE IN THE PRC 2584115 1/F, 5/FBuilding 41No. 258, Xinzhuan RoadSongjiang DistrictShanghaiPRC PRINCIPAL PLACE OF BUSINESS IN HONGKONG 3485 5/F, Manulife Place348 Kwun Tong RoadKowloonHong Kong AUDITORS 22 PricewaterhouseCoopersCertified Public Accountants and Registered Public InterestEntity Auditor22/F, Prince’s BuildingCentralHong Kong Corporate Information LEGAL ADVISORS As to Hong Kong lawWilson Sonsini Goodrich & Rosati ••• As to PRC lawHaiwen & Partners COMPLIANCE ADVISOR 811 Halcyon Capital Limited11/F, 8 Wyndham StreetCentralHong Kong HONG KONG SHARE REGISTRAR 1617 Tricor Investor Services Limited17/F, Far East Finance Centre16 Harcourt RoadHong Kong PRINCIPAL BANKS Bank of ShanghaiChina Merchants BankIndustrial and Commercial Bank of ChinaBank of Ningbo http://www.scientechmed.com/ COMPANY WEBSITE http://www.scientechmed.com/ 2022118 LISTING DATE November 8, 2022 STOCK CODE 2291 Financial Highlights 20221231247.731.6%20231231325.9 –Revenue increased by 31.6% from RMB247.7 million forthe year ended December 31, 2022 to RMB325.9 millionfor the year ended December 31, 2023. 20221231219.731.5%20231231288.8 –Gross profit increased by 31.5% from RMB219.7 millionforthe year ended December 31,2022 to RMB288.8million for the year ended December 31, 2023. –Research and development expenses increased by 14.3%from RMB53.9 million for the year ended December 31,2022 to RMB61.6 million for the year ended December 31,2023. 202212315 3 . 914.3%2023123161.6 –Net other income of RMB18.4 million was recorded for theyear ended December 31, 2023 as compared to net otherlosses of RMB69.5 million for the year ended December31, 2022. 2023123118.42022123169.5 20231231151.52022123119.8 –Profit attributable to owners of the Company of RMB151.5million was recorded for the year ended December 31,2023as compared to a loss attributable to owners oftheCompany of RMB19.8 million for the year endedDecember 31, 2022. (1)20221231111.155.4%20231231172.6 –Thenon-IFRS adjusted net profit(1)increased by 55.4%from RMB111.1 million for the year ended December 31,2022 to RMB172.6 million for the year ended December31, 2023. 2 0 2 31 2310.57 –The Board recommends the payment of a final dividendof RMB0.57 per Share (tax inclusive) for the year endedDecember 31, 2023. Financial Highlights Notes: (1)(i)(ii)(iii)( i v ) (1)Adjusted net profit which is unaudited, represents profit/(losses)for the year after adding back (i) listing expenses, net of tax; (ii)net foreign exchange losses from the retranslation of the USD-denominatedredemption liabilities;(iii)interest expense onredemption liabilities; and (iv) share-based payment expenses. Weeliminate the impacts of these items that our management do notconsider to be indicative of our operating performance, as theyare either non-cash items or non-recurring expenses. (2) 2Certain amounts and percentage figures included in this reporthavebeen subject to rounding.Accordingly,figures shown astotals in certain tables may not be an arithmetic aggregation ofthefigures preceding them. Any discrepancies in any table orchart between the total shown and the sum of the amounts listedare due to rounding. Chairman’s Statement Dear Shareholders of ScienTech Medical, First of all, on behalf of the Board, management and staff ofScienTech Medical, I would like to extend my sincere greetingswith best wishes to our Shareholders and friends from all walksof life. 2023202211 Time flies, 2023 was the first full financial year of